(add mechanism 1-8)

A. Scopolamine
• Motion Sickness; preoperatively to reduce secretions • Anti-muscarinic toxicities (mydriasis & cycloplegia; decreased secretions & sweating; flushing; bradycardia (low doses); tachycardia (high doses); urinary retention; drowsiness, hallucinations, coma)
Typical Anti-psychotics (Chlorpromazine, Haloperidol, Thioridazine)
• Lactation; Extrapyramidal effects (parkinsonism, akathisia (motor restlessness), tardive dyskinesia (lip smacking, jaw movements, etc.)); anti-cholinergic effects (antimuscarinic, alpha-antagonistic (orthostatic hypotension), and anti-histamine (sedation)). Toxicities are a tradeoff—higher extrapyramidal effects coincide with lower anticholinergic effects and vice-versa. The higher the extrapyramidal effects, the higher the potency (haloperidol > chlorpromazine > thioridazine)
Atypical anti-psychotics (Clozapine)
• NO extrapyramidal effects or lactation; agranulocytosis (fatal); Neuroleptic Malignant Syndrome (catatonia, autonomic instability, stupor); anti-cholinergic effects as above B. Opiate Agonists (Morphine, Meperidine, Codeine, Methadone, Heroin, Fentanyl)
• Act at mu, kappa, delta receptors in CNS • Analgesia; Antitussive (Codeine); opiate addiction (Methadone); antidiarrheal (loperamide) • CNS depression; nausea; respiratory depression; constipation; urinary retention; dependence
Opiate Mixed Agonists-Antagonists (Pentazocine)
• Same as agonists but will cause withdrawal in those dependent on agonists

Opiate Antagonists (Naloxone, Naltrexone)
• Narcotic overdose (no effect if used alone)

• Anemia associated with renal failure
RU486 (Mifepristone)

• Uterine bleeding, possible incomplete abortion

C. Acarbose
• Alpha-glucosidase inhibitor—decreases absorption of glucose • Flatulence; diarrhea; abdominal cramping

D. Losartan
• Similar to ACE inhibitors but no cough (decreased bradykinin activation)

E. Myasthenia Gravis Drugs
• Diagnosis (edrophonium); long-term treatment (Neostigmine, Pyridostigmine); open-angle glaucoma; reversal F. Leuprolide
• GnRH analog desensitization of pituitary receptor decreased FSH, LH secretion • Transient excess testosterone production (prevent by combining with flutamide); impotence, hot flashes, tumor G. Flutamide
• Blocks inhibitory effects of testosterone on GnRH release H. Aminoglutethimide
• Inhibits Cholesterol pregnenelone conversion (like metyrapone) • Metastatic breast cancer (decreased estrogen) • Induces P450; transient CNS depression; rash

I. Metformin
• Decreases gluconeogenesis; improves lipid profile (HDL rises, LDL falls) • NIDDM – lower risk of hypoglycemia • GI side effects; lactic acidosis (rare); long-term interference w B12 absorption

J. Stool Softeners (psyllium, methylcellulose)
• Absorbs water and softens stool bulk peristalsis • Constipation
Mechanism, clinical use, and toxicity of dermatologic agents:
CORTICOSTEROIDS: Synthesized in the zona fascilculata of the adrenal cortex. Cortisol and Cortisone
1) Glucocorticoids are catabolic. They influence carbohydrate and fat metabolism to insure adequate delivery of
2) Decrease intestinal uptake of calcium; increase renal excretion of calcium (contribute to osteoporosis).
3) Supress the inflammatory response – Decrease edema, fibrin deposition, capillary dilatation, leukocyte
migration and phagocytic activity. Inhibit prostaglandin and leukotriene production by inhibiting
phospholipase A2.

4) Include: Cortisone (short acting), Prednisone (intermediate acting), Prednisolone (similar to prednisone but no
hepatic metabolism for activity), Methylprednisolone (similar to prednisolone but better anti-inflamatory and less mineralocorticoid effects), Triamcinolone (5x more potent than cortisol), Dexamethasone (long acting) & Beclomethasone (long acting available as aerosol). 5) Toxicity:
hirsutism, skin thinning, poor wound healing, striae, acne and purpura. b) Other: hyperglycemia, hypertension, cataracts, glaucoma, peptic ulcer disease, osteoporosis, and

1) Used to treat the following dermatologic diseases: Acne, psoriasis, icthyosis and has a potential benefit in early
2) Toxicity: in skin it can cause desquamation, dry skin and pruritus, erythema. ANTIFUNGALS:
1) Polyene antibiotics are fungicidal against both filamentous and yeastlike fungi including Histoplasma,
Blastomyces, Coccidioides, Cryptococcus, Candida, Aspergillus and Sporothrix. Polyenes interact with sterols
in the cytoplasmic membrane of fungi leading to rapid leakage of small molecules and death. Sensitive fungi
have ergosterol in their membranes.
a) Amphotercin B: Broad spectrum to treat systemic fungal infections. Side effects: Fever, chills, impaired
renal function, anemia, thrombocytopenia. b) Nystatin (Mycostatin): Similar to A but used primarily in topical preparations. Use in Candida infections
Block the synthesis of fungal cell membrane ergosterols.
a) Miconazole & Clomitrazole: Miconazole is the only imidazole that can be administered IV; clotrimazole
is only used topically. i) Intravenous miconazole is rarely used due to toxicity. Treats ringworm, vulvovaginal candidiasis b) Ketoconazole: Oral administration only. Causes gynecomastia.
a) Flucytosine: Administer with amphotercin B in the treatment of cryptococcal meningitis and other
systemic infections (synergistic).
b) Griseofulvin: Binds to keratin, treat Tineas (capitis, corporis etc),
Other new pharmacologic agents:
1) Erythopoietin (EPO): RBC growth factor. Produced in kindneys. Recombinant form available (epoietin
a) Use for tx of Anemia 2nd to renal failure or zidovudine (AZT) use HIV patients.
b) Use for tx of Anemia 2nd to chemo, or to stimulate rbc production prior to surgery or to facilitate autologous c) Side effects: Clotting of dialysis tubing and hypertension. 2) RU486 (Mifrepristone): Abortificen. Blocks progesterone receptors and thereby progesterone support of
pregnancy. 80% effective, 95% if used with prostaglandins. a) Complications include incomplete abortion (2%), ongoing pregnancy (1%), hemorrhage during D&C Know About.
1) Complications of empiric antibiotic use: a) Resistance: Must take into account susceptibility patterns of local settings. Must distinguish between community vs. nosocomial infection, and must take into account the patient’s immune status. b) Fungal Infections: Due to destruction of normal flora. (candidiasis). c) Other complications: C. Diff Pseudomembranous colitis. Gentamicin ototoxicity (must monitor levels), Sulfonamides and Penicillin allergic reactions. a) Heparin osteoporosis with chronic use. Thombocytopenia – usually transient and mild. b) Thiazides Hyperlipidemia, hypokalemia. 3) Drugs that block/increase hepatic drug metabolism: a) Cimetidine: Histamine analog that cab reduce hepatic blood flow and slow clearance of other drugs and also reduces b) Ethanol: Chronic use induces hepatic microsomal enzymes and may enhance metabolism of other drugs. c) Phenobarbital: Increased phenobarbital levels in patients that have ethanol, chloramphenicol or valproic acid on board, since it has microsomal enzyme metabolism. d) Phenytoin (Dilantin): same as Phenobarb and ETOH Metabolized by microsomal enzymes. e) Rifampin: Causes jaundice and hepatotoxicity, also interacts with C p-450 system. a) Partial agonists/agonist: Drugs that bind to receptors and stimulate them. b) Antagonists: are drugs that bind to receptors and decrease or block the effect of an agonist. They do not Competitive antagonist: Reversibly binds to the receptor and prevents binding of the agonist. ii) Non competitive antagonist: Usually binds to the receptor irreversibly and prevents any agonist action. c) Efficacy: Maximal effect produced by a drug. d) Potency: Activity of a drug compared to a reference standard; depends on the drug’s ability to reach the receptors and its affinity to the receptor. 5) Drug efficacy and potency as demonstrated on dose-response curves: a) ED50 (effect dose)- Dose which produces half-maximal response (ie., observed effect seen in 50% of patients); used as a measure of potency (the lower the ED50, the more potent the drug). b) TD50 (toxic dose)- Minimum dose which produces a specific toxic effect in 50% of individual (or c) LD50 (lethal dose)- Minimum dose which kills 50% of animals. d) Therapeutic index- Ratio of dose required to produce a toxic effect to the dose needed for a therapeutic effect. Used as an indication of drug safety. Expressed as : TI= TD50 or TI= LD50 You want drugs with a high therapeutic index (low 6) Pharmacogenetics: drugs whose metabolism is affected by inheritance: a) Isoniazid: Most commonly used drug for the treatment of TB. i) Inhibits biosynthesis of mycolic acids. ii) Metabolized in the liver (acetylated); speed of acetylation and consequently isoniazid’s half life is genetically determined (fast vs. slow acetylators). A. Anemia is due to increased destruction or decreased production.
B. Microcytic anemia
1. Iron – absorbed in the duodenum and proximal jejunum. Iron deficiency seen in premature infants,
pregnant and lactating women. Ferrous oral salts can be given; give for 3-6 months to replenish iron
stores. IV iron can also be given.
a. N/V, cramps, constipation, diarrhea – dose-related so decrease the dose
b. Acute
toxicity – seen in kids, necrotizing gastroenteritis followed by shock, lethargy, dyspnea
c. Chronic iron toxicity - hemochromatosis C. Megaloblastic anemia – lack of vitamins needed for normal DNA synthesis, so the RBC gets biggger
1. Vitamin B12 (normally obtained in meats), requires intrinsic factor for absorption (pernicious anemia
decreases absorption), gastrectomy also decreases absorption. B12 is stored in the body (years supply)
a. B12 deficiency also shows nervous defects
b. B12 shots can be given if oral absorption is a problem
c. Folate will NOT correct neurological features, but WILL help with the anemia
2. Folic Acid – from green leafy veggies, body stores of folate are lower (1-6 months)
a. Deficiency doesn’t have neurological deficits b. Folic acid is well absorbed orally 1. Erythropoietin – used for renal failure, bone diseases, chemotherapy
a. Toxicity – too rapid increase in hematocrit can lead to HTN, thrombotic complications 2. Colony stimulating factors (G-CSF, GM-CSF)
a. Increase recovery after myelosuppressive chemotherapy or BMT 8. Prevention/treatment of cerebrovascular disease K. Aspirin
1. Irreversibly blocks cyclooxygenase, = inhibits thromboxane (TxA2) formation from platelets
1. Inhibits platelet aggregation (inhibits ADP pathway) 2. Decreases TIAs, completed strokes, unstable angina pectoris 3. Diarrhea leukopenia in 1% (must monitor white count)
M. Thrombolytics – catalyze formation of plasmin, a generalized lytic state in body is produced
allergic reactions possible
2. Urokinase
3. Tissue plasminogen activators (t-PA) – expensive, from recombinant DNA
A. Drugs that alter Pain
1. Aspirin – 1st line drug, GI problems 2. NSAIDS 3. COX-2 inhibitors – less GI problems that Decrease Progression
1. Methotrexate and immunosuppressives – more toxic side effects 2. Gold – dermatitis is common side effect 10. Vaccines: indications, potential side effects 1. Active immunization – antigen is given so host develops antibodies (long protection)
2. Passive – immunoglobins are given (short term protection)
a. Give to those recently exposed (Tetanus, Botulinum, HBV, Rabies) or to travelers (Polio, tetanus,
Measles, diphtheria)
1. Giving live attenuated vaccines may cause the disease (eg. Polio vaccine) 2. Killed vaccine will not cause the disease 3. Allergic reactions are possible 11. Chemotherapeutic agents: risk of possible secondary cancer

Source: http://brownmed.tripod.com/pdfs/pharm.pdf

Microsoft word - dr mary flynn olive oil talk july 2013

Extra virgin olive oil and health Mary M. Flynn, PhD, RD, LDN. Associate Professor of Medicine, Clinical, Brown University Research Dietitian, The Miriam Hospital. 401.793.2621 Founder of “The Olive Oil Health Initiative of The Miriam Hospital at Brown University “ People raised on diets that daily include extra virgin olive oil (EVoo) have lower rates of most chronic diseases, such as le

File://c:\users\msteinke\desktop\new article\technique\2000\1\a

USA Gymnastics Online: Technique: Approaches to Treating ADHD Alternative Medical Approaches to Treating Attention Deficit/Hyperactivity Disorder By Larry Nassar, D.O., A.T.C., USA Gymnastics National Medical Coordinator Michigan State University, College of Osteopathic Medicine, Assistant Professor, Department of Family & Community Medicine Attention Deficit Hyperactivity Disorder (ADHD

Copyright © 2010-2018 Pharmacy Drugs Pdf